Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
These findings support the benefit of abemaciclib in women with HR+, HER2- ABC/MBC in the real-world and complement data from MONARCH 2 and 3 clinical trials.
Authors
- Rosalind Jarvis
- Waleed Badreldin
- Gavin Harper (ORCID: https://orcid.org/0000-0002-1704-9447)
- Carlo Palmieri (ORCID: https://orcid.org/0000-0001-9496-2718)
- Judy King
- Walid Fakhouri
- Mark A. Nathan
Institutions
- University of Liverpool (GB)
- Eli Lilly (United States) (US)
- Royal Free London NHS Foundation Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Adelphi Group (United Kingdom) (GB)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1186/s12885-025-14526-w
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company